These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 20419486)
21. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine. Doesch AO; Celik S; Ehlermann P; Frankenstein L; Zehelein J; Koch A; Katus HA; Dengler TJ Transplantation; 2007 Oct; 84(8):988-96. PubMed ID: 17989604 [TBL] [Abstract][Full Text] [Related]
22. [A New Insight on Anti-Ischemic Action of Ivabradine in Patients With Stable Angina]. Kobalava ZD; Shavarov AA; Kiyakbaev GK Kardiologiia; 2017 Mar; 57(3):68-74. PubMed ID: 28762939 [TBL] [Abstract][Full Text] [Related]
23. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Sulfi S; Timmis AD Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297 [TBL] [Abstract][Full Text] [Related]
24. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R; Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635 [TBL] [Abstract][Full Text] [Related]
25. Ivabradine: a new frontier in the treatment of stable coronary artery disease and chronic heart failure. Gammone MA; Riccioni G; D'Orazio N Clin Ter; 2020; 171(5):e449-e453. PubMed ID: 32901791 [TBL] [Abstract][Full Text] [Related]
26. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. Fasullo S; Cannizzaro S; Maringhini G; Ganci F; Giambanco F; Vitale G; Pinto V; Migliore G; Torres D; Sarullo FM; Paterna S; Di Pasquale P J Card Fail; 2009 Dec; 15(10):856-63. PubMed ID: 19944362 [TBL] [Abstract][Full Text] [Related]
27. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Vilaine JP Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639 [TBL] [Abstract][Full Text] [Related]
29. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L; Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495 [TBL] [Abstract][Full Text] [Related]
30. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease. Borer JS; Deedwania PC; Kim JB; Böhm M Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557 [TBL] [Abstract][Full Text] [Related]
31. Novel If current inhibitor ivabradine: safety considerations. Savelieva I; Camm AJ Adv Cardiol; 2006; 43():79-96. PubMed ID: 16936474 [TBL] [Abstract][Full Text] [Related]
32. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. Monnet X; Ghaleh B; Colin P; de Curzon OP; Giudicelli JF; Berdeaux A J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904 [TBL] [Abstract][Full Text] [Related]
33. Selective pharmacological inhibition of the pacemaker channel isoforms (HCN1-4) as new possible therapeutical targets. Koncz I; Szél T; Jaeger K; Baczkó I; Cerbai E; Romanelli MN; Gy Papp J; Varró A Curr Med Chem; 2011; 18(24):3662-74. PubMed ID: 21774761 [TBL] [Abstract][Full Text] [Related]
34. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Reil JC; Reil GH; Böhm M Trends Cardiovasc Med; 2009 Jul; 19(5):152-7. PubMed ID: 20005474 [TBL] [Abstract][Full Text] [Related]
35. Ivabradine: the hope for a good treatment of ischemic heart disease. Riccioni G Curr Med Chem; 2013; 20(14):1817-23. PubMed ID: 23394554 [TBL] [Abstract][Full Text] [Related]
36. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Busseuil D; Shi Y; Mecteau M; Brand G; Gillis MA; Thorin E; Asselin C; Roméo P; Leung TK; Latour JG; Des Rosiers C; Bouly M; Rhéaume E; Tardif JC Cardiology; 2010; 117(3):234-42. PubMed ID: 21212673 [TBL] [Abstract][Full Text] [Related]
37. Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review. Petite SE; Bishop BM; Mauro VF Am J Ther; 2018; 25(2):e247-e266. PubMed ID: 26910057 [TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. López-Bescós L; Filipova S; Martos R Cardiology; 2007; 108(4):387-96. PubMed ID: 17890862 [TBL] [Abstract][Full Text] [Related]
39. Influence of ivabradine on reverse remodelling during mechanical unloading. Navaratnarajah M; Ibrahim M; Siedlecka U; van Doorn C; Shah A; Gandhi A; Dias P; Sarathchandra P; Yacoub MH; Terracciano CM Cardiovasc Res; 2013 Feb; 97(2):230-9. PubMed ID: 23079200 [TBL] [Abstract][Full Text] [Related]